1. JCCT
  2. All Volumes and Issues
  3. Volume 11, Number 1, 2017
  4. Correlation between in silico and in vitro Results of 1-(Benzoyloxy)urea and its Derivatives as Potential Anti-Cancer Drugs

Correlation between in silico and in vitro Results of 1-(Benzoyloxy)urea and its Derivatives as Potential Anti-Cancer Drugs

JCCT.
2017;
Volume 11, Number 1
: pp. 19 – 24
https://doi.org/10.23939/chcht11.01.019
Authors: 

Suko Hardjono, Siswandono Siswodihardjo, Purwanto Pramono and Win Darmanto

Suko Hardjono-1, Siswandono Siswodihardjo-1, Purwanto Pramono-1 and Win Darmanto-2

  1. Faculty of Pharmacy, Universitas Airlangga, Jl. Darmawangsa Dalam Surabaya 60282, Indonesia, suko.hardjono@yahoo.com
  2. Faculty of Science and Technology, Universitas Airlangga Surabaya, Indonesia;

1-(Benzoyloxy)urea and its derivatives were synthesized by modified Scotten-Bauman reaction with adding benzoyl chloride or homologs to hydroxyurea in tetrahydrofuran. Structure characterization was conducted based on ultra-violet (UV-VIS) spectrum, infrared (FT-IR), H nucleus magnetic resonance (1H NMR), C nuclear magnetic resonance (13C NMR) and mass spectrometry (MS). In silico test to predict anti-cancer activity of 1-(benzoyloxy)urea and its derivatives in ribonucleotide reductase enzyme (PDB: 2EUD) was done using Molegro Program. The anti-cancer activity test was performed in vitroby using MTT method to HeLa cell lines. In silico test result (Rerank Score) was correlated relative to anti-cancer activity (log1/IC50). There was a significant linear relationship between in vitroand in silico anti-cancer activity.

1-(benzoyloxy)urea
derivatives
in silico test
in vitrotest
rerank score

[1] www.depkes.go.id.
[2] http://www.depkes.go.id/resources/download/general/ Hasil%20Riskesdas%202013.pdf.; 27/4/2015
[3] Wiestler O., Haendler B. and Mumberg D.: Cancer Stem Cells, Novel Concepts and Prospects for Tumor Therapy, Ernst Schering Found. Symp. Proc., Germany, Berlin 2007.
[4] Navarra P. and Preziosi P.: Crit. Rev. Oncology/Hematology, 1999, 29, 249.
[5] Khayat A., Guimaraes A., Cardoso P. et al.: Genet. Mol. Biol., 2004, 27, 115.
[6] Chabner B. and Calabresi P.: Chemotherapy of Neoplastic Diseases. [in:] Goodman&Gilman’s, The Pharmacological Basis of Therapeutics, 10th edn. McGraw-Hill, New York 2001, 1388-1445.
[7] http://www.komputasi.lipi.go.id. 16/12/2007.
[8] Jenzen F.: Introduction to Computational Chemistry, 2nd edn. Odense, Denmark 2007.
[9] Korolkovas A.: Essentials of Medicinal Chemistry, 2nd edn. John Wiley and Sons, New York, Singapore 1988.
[10] Topliss J.: J. Med. Chem, 1972, 15, 1006.
[11] Xu H., Faber C., Uchiki T. et.al.: PNAS, 2006, 103, 4028.
[12] Clayden J., Geeves N. and Warren S.: Organic Chemistry, 2nd edn. Oxford University Press, NY 2012.
[13] Zinner G. and Staffel R.: Arc. Pharm. Ber. Ges., 1969, 302, 438.
[14] Siverstein R., Webster F. and Kiemle D.: Spectrofotometric Identification of Organic Compound, 7th edn. John Wiley and Sons Inc., NY 2005.
[15] http://ccrcfarmasiugm.wordpress.com/protokol. 20/3/2012.
[16] Hardjono S., Siswodihardjon S., Pramono P. and Darmanto W.: Curr. Drug Disc. Technol., 2016, 13, 101.